Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D00YDN
|
|||
| Former ID |
DIB014242
|
|||
| Drug Name |
CXR-1002
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Phase 1 | [1] | |
| Company |
CXR Biosciences Ltd
|
|||
| Structure |
 |
Download2D MOL |
||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Serine/threonine-protein kinase pim-1 (PIM1) | Target Info | Inhibitor | [2] |
| KEGG Pathway | Jak-STAT signaling pathway | |||
| MicroRNAs in cancer | ||||
| Acute myeloid leukemia | ||||
| NetPath Pathway | IL9 Signaling Pathway | |||
| IL5 Signaling Pathway | ||||
| IL2 Signaling Pathway | ||||
| TGF_beta_Receptor Signaling Pathway | ||||
| TCR Signaling Pathway | ||||
| Pathway Interaction Database | GMCSF-mediated signaling events | |||
| Validated targets of C-MYC transcriptional activation | ||||
| Role of Calcineurin-dependent NFAT signaling in lymphocytes | ||||
| IL5-mediated signaling events | ||||
| IL3-mediated signaling events | ||||
| C-MYB transcription factor network | ||||
| WikiPathways | Ectoderm Differentiation | |||
| Hematopoietic Stem Cell Differentiation | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800034732) | |||
| REF 2 | 123 Antitumor activity of CXR1002, a novel anti-cancer clinical phase compound that induces ER stress and inhibits PIM kinases: Human tumor xenograft efficacy and in vitro mode of action. EJC Supplements, 2010; 8(7):45-46. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.